Scottish bio-tech company, BioCaptiva, has developed a novel next generation “liquid biopsy” technology device that could revolutionise the early diagnosis and monitoring of difficult to detect cancers.
The University of Edinburgh spin-out has raised over £1m in seed funding from Archangels and Scottish Enterprise, to help develop the technology.
To prepare the company for this next stage in its development, BioCaptiva has appointed Dr. Frank Armstrong FRCPE as non-executive chairman and Dr Stephen Little as a non-executive director.
Read more HERE.
